After signing up, you'll start to receive regular news updates from us.
Metabolon Awarded Patent for Metabolomics Software
Complete the form below to unlock access to ALL audio articles.
Metabolon, Inc. announced that the company has been awarded a patent for its proprietary metabolomics software, Visual PHIL™, which provides analysis and a unique visual display of metabolomic data. The software enables the analysis of a series of raw and complex data sets being generated from a variety of instruments into one comprehensive visual display that can indicate the presence of the selected metabolites across a group of samples.
“In the past, studies were conducted through analysis of one sample at a time. This technology allows us to see a comprehensive study view—in a visual display—which enables us to more quickly, and with a higher degree of certainty, identify compounds and hone in on biomarkers,” said Michael Milburn, chief scientific officer at Metabolon. “With Metabolon’s technology, we can offer our clients insight into the biochemical and physiological state of a sample to further research in areas like toxicology and cell line development.”
Using the Visual PHIL technology, Metabolon has conducted over 200 commercial studies as well as identified biomarkers associated with a variety of indications which it is using in the commercial development of several diagnostic products.
“We have long recognized Visual PHIL as a must-have technology for metabolomics research and it has served as a critical component to Metabolon’s service and diagnostic offerings,” commented John Ryals, Ph.D., CEO of Metabolon. “This patent is another strong addition to our IP portfolio, further reinforcing the company as the clear market leader in the industry.”
The awarded patent (US Patent 7’433’787), titled “A System, Method, and Computer Program Product Using a Database in a Computing System to Compile and Compare Metabolomic Data Obtained from a Plurality of Samples”, is the latest addition to Metabolon’s extensive IP portfolio consisting of over 80 US and worldwide patents and patent applications, including broad metabolomics methods, data analysis and biomarker patents, as well as focused product patents.
